Cyclenium enters into drug discovery collaboration with Haplogen
Under the deal, Cyclenium’s CMRT Technology-derived QUEST Library and associated hit-to-lead optimization expertise will be combined with Haplogen’s haploid genetics technology and expertise in host target identification, validation
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.